Skip to main content
SpringerLink
Log in

Growth and endocrine function in thalassemia major in childhood and adolescence

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Thalassemia major is an inherited hemoglobin disorder characterized by chronic anemia and iron overload due to transfusion therapy and gastrointestinal absorption. Iron overload causes most of the associated mortality and morbidity and frequently involves the endocrine glands. Aim: To review the most pertinent literature on the topic. Methods: One hundred and twenty-three papers were evaluated. Results: Disproportionate short stature is frequent and becomes more evident at puberty because of the lack of growth spurt. Later on, partial height recovery may occur. Long-term treatment with recombinant human GH seems ineffective to improve final height. Pubertal development is characterized by a clinical spectrum ranging from hypogonadism to a simple delay in starting and developing of puberty. Hormonal replacement is mandatory in cases of absent or arrested puberty. Pancreatic β-cells function may be impaired during adolescence or later on. Its impairment ranges from hyperinsulinemia, secondary to insulin resistance, with normal glucose tolerance to β-cells failure with insulindependent diabetes mellitus. Primary hypothyroidism may affect thalassemic patients from the second decade of life. The thyroid dysfunction may be reversible (if an intensive chelation therapy regimen is started in the precocious phase), stationary, or slowly progressive. Central hypothyroidism is less common and autoimmune thyroiditis absent. Conclusion: Despite the improvement of the treatment, the involvement of the endocrine system still burdens the life of these patients. Further therapeutic improvement would reasonably reduce morbidity and, hopefully, mortality of thalassemic patients and make the endocrine disorders easier to treat.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC; Italian Working Group on Endocrine Complications in Non-Endocrine Diseases. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab 2006, 19: 471–80.

    PubMed  Google Scholar 

  2. Constantoulakis M, Panagopoulos G, Augoustaki O. Stature and longitudinal growth in thalassemia major. A study of 229 Greek patients. Clin Pediatr (Phila) 1975, 14: 355–7/362-8.

    CAS  Google Scholar 

  3. Cavallo L, De Mattia D, Giobbe T, et al. Growth in homozygous β-thalassemia patients. In: Cavallo L, Job JC, New MI, eds. Growth Disorders: the State of the art. Serono Symposia No. 81. Rome: Raven Press. 1991, 47–54.

    Google Scholar 

  4. Garcia-Mayor RV, Andrade Olivie A, Fernández Catalina P, Castro M, Rego Iraeta A, Reparaz A. Linear growth in thalassemic children treated with intensive chelation therapy. A longitudinal study. Horm Res 1993, 40: 189–93.

    CAS  Google Scholar 

  5. Rodda CP, Reid ED, Johnson S, Doery J, Matthews R, Bowden DK. Short stature in homozygous β-thalassemia is due to disproportionate truncal shortening. Clin Endocrinol (Oxf) 1995, 42: 587–92.

    CAS  Google Scholar 

  6. Pérignon F, Brauner R, Souberbielle JC, de Montalembert M, Girot R. Growth and endocrine function in major thalassemia. Arch Fr Pediatr 1993, 50: 657–63.

    PubMed  Google Scholar 

  7. Theodoridis C, Ladis V, Papatheodorou A, et al. Growth and management of short stature in thalassaemia major. J Pediatr Endocrinol Metab 1998, 11(Suppl 3): 835–44.

    PubMed  Google Scholar 

  8. Raiola G, Galati MC, De Sanctis V, et al. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab 2003, 16(Suppl 2): 259–66.

    PubMed  Google Scholar 

  9. Low L. Growth of children with β-thalassemia major. Indian J Pediatr 2005, 72: 159–64.

    PubMed  Google Scholar 

  10. Shalitin S, Carmi D, Weintrob N, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005, 74: 93–100.

    CAS  PubMed  Google Scholar 

  11. De Virgiliis S, Congia M, Frau F, et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988, 113: 661–9.

    PubMed  Google Scholar 

  12. De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B. Effect of different treatment regimes on linear growth and final height in beta-thalassaemia major. Clin Endocrinol (Oxf) 1994, 40: 791–8.

    Google Scholar 

  13. De Sanctis V. Growth and puberty and its management in thalassemia. Horm Res 2002, 58(Suppl 1): 72–9.

    PubMed  Google Scholar 

  14. Arcasoy A, Cavdar A, Cin S, et al. Effects of zinc supplementation on linear growth in beta-thalassemia (a new approach). Am J Hematol 1987, 24: 127–36.

    CAS  PubMed  Google Scholar 

  15. Eshghi P, Alavi S, Ghavami S, Rashidi A. Growth impairment in beta-thalassemia major: the role of trace element deficiency and other potential factors. J Pediatr Hematol Oncol 2007, 29: 5–8.

    CAS  PubMed  Google Scholar 

  16. Mehdizadeh M, Zamani G, Tabatabaee S. Zinc status in patients with major beta-thalassemia. Pediatr Hematol Oncol 2008, 25: 49–54.

    CAS  PubMed  Google Scholar 

  17. Filosa A, Di Maio S, Baron I, Esposito G, Galati MG. Final height and body disproportion in thalassaemic boys and girls with spontaneous or induced puberty. Acta Paediatr 2000, 89: 1295–301.

    CAS  PubMed  Google Scholar 

  18. Caruso-Nicoletti M, De Sanctis V, Raiola G, Skordis N, Mancuso M, Coco M, Wonke B. No difference in pubertal growth and final height between treated hypogonadal and non-hypogonadal thalassemic patients. Horm Res 2004, 62: 17–22.

    CAS  PubMed  Google Scholar 

  19. Cavallo L, Gurrado R, Gallo F, Zacchino C, De Mattia D, Tatò L. Growth deficiency in polytransfused β-thalassemia patients is not growth hormone dependent. Clin Endocrinol 1997, 46: 701–6.

    CAS  Google Scholar 

  20. Caruso-Nicoletti M, De Sanctis V, Capra M, et al. Short stature and body proportion in thalassaemia. J Pediatr Endocrinol Metab 1998, 11(Suppl 3): 811–6.

    PubMed  Google Scholar 

  21. Low CK, Kwan YW, Cheung PT, et al. The effect of platyspondyly and pubertal growth spurt on the stature of patients with beta-thalassaemia major. Chin Med J (Engl) 1998, 111: 731–5.

    CAS  Google Scholar 

  22. Skordis N, Michaelidou M, Savva SC, et al. The impact of genotype on endocrine complications in thalassaemia major. Eur J Haematol 2006, 77: 150–6.

    CAS  PubMed  Google Scholar 

  23. Shehadeh N, Hazani A, Rudolf MC, Peleg I, Benderly A, Hochberg Z. Neurosecretory dysfunction of growth hormone secretion in thalassemia major. Acta Paediatr Scand 1990, 79: 790–5.

    CAS  PubMed  Google Scholar 

  24. Chatterjee R, Katz M, Cox T, Bantock H. Evaluation of growth hormone in thalassaemic boys with failed puberty: spontaneous versus provocative test. Eur J Pediatr 1993, 152: 721–6.

    CAS  PubMed  Google Scholar 

  25. Katzos G, Harsoulis F, Papadopoulou M, Athanasiou M, Sava K. Circadian growth hormone secretion in short multitransfused prepubertal children with thalassaemia major. Eur J Pediatr 1995, 154: 445–9.

    CAS  PubMed  Google Scholar 

  26. Roth C, Pekrun A, Bartz M, et al. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997, 156: 777–83.

    CAS  PubMed  Google Scholar 

  27. Soliman AT, elZalabany MM, Mazloum Y, et al. Spontaneous and provoked growth hormone (GH) secretion and insulin-like growth factor I (IGF-I) concentration in patients with beta thalassaemia and delayed growth. J Trop Pediatr 1999, 45: 327–37.

    CAS  PubMed  Google Scholar 

  28. Karydis I, Karagiorga-Lagana M, Nounopoulos C, Tolis G. Basal and stimulated levels of growth hormone, insulin-like growth factor-I (IGF-I), IGF-I binding and IGF-binding proteins in beta-thalassemia major. J Pediatr Endocrinol Metab 2004, 17: 17–25.

    CAS  PubMed  Google Scholar 

  29. Mclntosh N. Endocrinopathy in thalassaemia major. Arch Dis Child 1976, 51: 195–201.

    Google Scholar 

  30. Vannasaeng S, Ploybutr S, Visutkul P, Tandhanand S, Suwanik R, Wasi P. Endocrine function in thalassaemia. Clin Endocrinol (Oxf) 1981, 14: 165–73.

    CAS  Google Scholar 

  31. Masala A, Meloni T, Gallisai D, et al. Endocrine functioning in multitransfused prepubertal patients with homozygous beta-thalassemia. J Clin Endocrinol Metab 1984, 58: 667–70.

    CAS  PubMed  Google Scholar 

  32. Leger J, Girot R, Crosnier H, Postel-Vinay MC, Rappaport R. Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect. J Clin Endocrinol Metab 1989, 69: 453–6.

    CAS  PubMed  Google Scholar 

  33. Soliman AT, El Banna N, Abdel Fattah M, ElZalabani MM, Ansari BM. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 1998, 47: 541–8.

    CAS  PubMed  Google Scholar 

  34. Soliman AT, El Banna N, Ansari BM. GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia. Eur J Endocrinol 1998, 138: 394–400.

    CAS  PubMed  Google Scholar 

  35. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in beta-thalassemia major in a developing country. J Pediatr Endocrinol Metab 2000, 13: 651–6.

    CAS  PubMed  Google Scholar 

  36. Chrysis DC, Alexandrides TK, Koromantzou E, et al. Novel application of IGF-I and IGFBP-3 generation tests in the diagnosis of growth hormone axis disturbances in children with beta-thalassaemia. Clin Endocrinol (Oxf) 2001, 54: 253–9.

    CAS  Google Scholar 

  37. Aydinok Y, Darcan S, Polat A, et al. Endocrine complications in patients with beta-thalassemia major. J Trop Pediatr 2002, 48: 50–4.

    PubMed  Google Scholar 

  38. Karamifar H, Karimi M, Amirhakimi G, Sharbatialaei M, De Sanctis V. Reduced insulin growth factor I concentrations in iron-overloaded beta thalassaemic patients with normal growth hormone secretion and liver function. Pediatr Endocrinol Rev 2004, 2(Suppl 2): 256–8.

    PubMed  Google Scholar 

  39. De Sanctis V, Eleftheriou A, Malaventura C; Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004, 2(Suppl 2): 249–55.

    PubMed  Google Scholar 

  40. Moayeri H, Oloomi Z. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. Arch Iran Med 2006, 9: 329–34.

    CAS  PubMed  Google Scholar 

  41. Pintor C, Cella SG, Manso P, et al. Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J Clin Endocrinol Metab 1986, 62: 263–7.

    CAS  PubMed  Google Scholar 

  42. Leheup BP, Cisternino M, Bozzola M, et al. Growth hormone response following growth hormone releasing hormone injection in thalassemia major: influence of pubertal development. J Endocrinol Invest 1991, 14: 37–40.

    CAS  PubMed  Google Scholar 

  43. Danesi L, Scacchi M, De Martin M, et al. Evaluation of hypothalamic-pituitary function in patients with thalassemia major. J Endocrinol Invest 1992, 15: 177–84.

    CAS  PubMed  Google Scholar 

  44. DeLuca G, Maggiolini M, Bria M, et al. GH secretion in thalassemia patients with short stature. Horm Res 1995, 44: 158–63.

    CAS  PubMed  Google Scholar 

  45. Postel-Vinay MC, Girot R, Leger J, et al. No evidence for a defect in growth hormone binding to liver membranes in thalassemia major. J Clin Endocrinol Metab 1989, 68: 94–8.

    CAS  PubMed  Google Scholar 

  46. Saenger P, Schwartz E, Markenson AL, et al. Depressed serum somatomedin activity in beta-thalassemia. J Pediatr 1980, 96: 214–8.

    CAS  PubMed  Google Scholar 

  47. Werther GA, Matthews RN, Burger HG, Herington AC. Lack of response of nonsuppressible insulin-like activity to short term administration of human growth hormone in thalassemia major. J Clin Endocrinol Metab 1981, 53: 806–9.

    CAS  PubMed  Google Scholar 

  48. Lasco A, Morabito N, Gaudio A, et al. Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 2002, 25: 338–44.

    CAS  PubMed  Google Scholar 

  49. Low LCK, Postel-Vinay MC, Kwan EY, Cheung PT. Serum growth hormone (GH) binding protein, IGF-I and IGFBP-3 in patients with beta-thalassaemia major and the effect of GH treatment. Clin Endocrinol (Oxf) 1998, 48: 641–6.

    CAS  Google Scholar 

  50. Caruso-Nicoletti M. Epidemiological assessment of GH deficiency in Thalassemic patients. J Endocrinol Invest 2006, 29(Suppl 5): 105–9.

    Google Scholar 

  51. Scacchi M, Danesi L, De Martin M, et al. Treatment with biosynthetic growth hormone of short thalassaemic patients with impaired growth hormone secretion. Clin Endocrinol (Oxf) 1991, 35: 335–9.

    CAS  Google Scholar 

  52. Low LC, Kwan EY, Lim YJ, Lee AC, Tarn CF, Lam KS. Growth hormone treatment of short Chinese children with beta-thalassaemia major without GH deficiency. Clin Endocrinol (Oxf) 1995, 42: 359–63.

    CAS  Google Scholar 

  53. De Sanctis V, Urso L. Growth and thalassemia. Minerva Pediatr 1997, 49: 121–8.

    PubMed  Google Scholar 

  54. Low LC. Growth, puberty and endocrine function in beta-thalassaemia major. J Pediatr Endocrinol Metab 1997, 10: 175–84.

    CAS  PubMed  Google Scholar 

  55. Cavallo L, Gurrado R, Zecchino C, et al. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency. J Pediatr Endocrinol Metab 1998, 11(Suppl 3): 845–9.

    PubMed  Google Scholar 

  56. Arcasoy A, Ocal G, Kemahli S, et al. Recombinant human growth hormone treatment in children with thalassemia major. Pediatr Int 1999, 41: 655–61.

    CAS  PubMed  Google Scholar 

  57. Katzos G, Papakostantinou-Athanasiadou E, Athanasiou-Metaxa M, Harsoulis F. Growth hormone treatment in short children with beta-thalassemia major. J Pediatr Endocrinol Metab 2000, 13: 163–70.

    CAS  PubMed  Google Scholar 

  58. Sartorio A, Conte G, Conti A, et al. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. J Endocrinol Invest 2000, 23: 356–61.

    CAS  PubMed  Google Scholar 

  59. Kwan EY, Tarn SC, Cheung PT, Low LC. The effect of 3 years of recombinant growth hormone therapy on glucose metabolism in short Chinese children with beta-thalassemia major. J Pediatr Endocrinol Metab 2000, 13: 545–52.

    CAS  PubMed  Google Scholar 

  60. Cavallo L, Acquafredda A, Zecchino C, et al. Recombinant growth hormone treatment in short patients with thalassemia major: results after 24 and 36 months. J Pediatr Endocrinol Metab 2001, 14: 1133–7.

    CAS  PubMed  Google Scholar 

  61. Masala A, Atzeni MM, Alagna S, et al. Growth hormone secretion in polytransfused prepubertal patients with homozygous beta-thalassemia. Effect of long-term recombinant GH (recGH) therapy. J Endocrinol Invest 2003, 26: 623–8.

    CAS  PubMed  Google Scholar 

  62. Wu KH, Tsai FJ, Peng CT. Growth hormone (GH) deficiency in patients with beta-thalassemia major and the efficacy of recombinant GH treatment. Ann Hematol 2003, 82: 637–40.

    CAS  PubMed  Google Scholar 

  63. Cavallo L, De Sanctis V, Cisternino M, et al. Final height in short polytransfused thalassemia major patients treated with recombinant growth hormone. J Endocrinol Invest 2005, 28: 363–6.

    CAS  PubMed  Google Scholar 

  64. Fung EB, Harmatz PR, Lee PD, et al; Multi-Centre Study of Iron Overload Research Group. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006, 135: 574–82.

    PubMed  Google Scholar 

  65. Allegra A, Capra M, Cuccia L, et al. Hypogonadism in beta-thalassemic adolescents: a characteristic pituitary-gonadal impairment. The ineffectiveness of long-term iron chelation therapy. Gynecol Endocrinol 1990, 4: 181–91.

    CAS  PubMed  Google Scholar 

  66. Soliman AT, elZalabany MM, Ragab M, et al. Spontaneous and GnRH-provoked gonadotropin secretion and testosterone response to human chorionic gonadotropin in adolescent boys with thalassaemia major and delayed puberty. J Trop Pediatr 2000, 46: 79–85.

    CAS  PubMed  Google Scholar 

  67. Al-Rimawi HS, Jallad MF, Amarin ZO, Obeidat BR. Hypothalamicpituitary-gonadal function in adolescent females with beta-thalassemia major. Int J Gynaecol Obstet 2005, 90: 44–7.

    CAS  PubMed  Google Scholar 

  68. Al-Rimawi HS, Jallad MF, Amarin ZO, Al Sakaan R. Pubertal evaluation of adolescent boys with beta-thalassemia major and delayed puberty. Fertil Steril 2006, 86: 886–90.

    CAS  PubMed  Google Scholar 

  69. Soliman AT, Nasr I, Thabet A, Rizk MM, El Matary W. Human chorionic gonadotropin therapy in adolescent boys with constitutional delayed puberty vs those with beta-thalassemia major. Metabolism 2005, 54: 15–23.

    CAS  PubMed  Google Scholar 

  70. Oerter KE, Kamp GA, Munson PJ, Nienhuis AW, Cassorla FG, Manasco PK. Multiple hormone deficiencies in children with hemochromatosis. J Clin Endocrinol Metab 1993, 76: 357–61.

    CAS  PubMed  Google Scholar 

  71. Berkovitch M, Bistritzer T, Milone SD, Perlman K, Kucharczyk W, Olivieri NF. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. J Pediatr Endocrinol Metab 2000, 13: 179–84.

    CAS  PubMed  Google Scholar 

  72. Christoforidis A, Haritandi A, Perifanis V, Tsatra I, Athanassiou-Metaxa M, Dimitriadis AS. MRI for the determination of pituitary iron overload in children and young adults with beta-thalassaemia major. Eur J Radiol 2007, 62: 138–42.

    PubMed  Google Scholar 

  73. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med 1990, 323: 713–9.

    CAS  PubMed  Google Scholar 

  74. Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf) 2000, 53: 33–42.

    CAS  Google Scholar 

  75. Jensen CE, Tuck SM, Old J, et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur J Haematol 1997, 59: 76–81.

    CAS  PubMed  Google Scholar 

  76. Chern JP, Lin KH, Tsai WY, et al. Hypogonadotropic hypogonadism and hematologic phenotype in patients with transfusion-dependent beta-thalassemia. J Pediatr Hematol Oncol 2003, 25: 880–4.

    PubMed  Google Scholar 

  77. Skordis N, Gourni M, Kanaris C, et al. The impact of iron overload and genotype on gonadal function in women with thalassaemia major. Pediatr Endocrinol Rev 2004, 2(Suppl 2): 292–5.

    PubMed  Google Scholar 

  78. Pomarède R, Girot R, Constant S, Rappaport R. Effect of hematologic treatment on the growth and puberty of children with thalassemia major. Arch Fr Pediatr 1984, 41: 255–9.

    PubMed  Google Scholar 

  79. Wang C, Tso SC, Todd D. Hypogonadotropic hypogonadism in severe beta-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy. J Clin Endocrinol Metab 1989, 68: 511–6.

    CAS  PubMed  Google Scholar 

  80. Skordis N, Petrikkos L, Toumba M, et al. Update on fertility in thalassaemia major. Pediatr Endocrinol Rev 2004, 2(Supp 2): 296–302.

    PubMed  Google Scholar 

  81. Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Clin Endocrinol (Oxf) 1995, 42: 581–6.

    Google Scholar 

  82. Arrigo T, Crisafulli G, Meo A, et al. Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major. J Pediatr Endocrinol Metab 1998, 11(Suppl 3): 863–6.

    PubMed  Google Scholar 

  83. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 2004, 104: 34–9.

    CAS  PubMed  Google Scholar 

  84. Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev 2004, 2(Suppl 2): 285–91.

    PubMed  Google Scholar 

  85. Kattamis C, Ladis V, Tsoussis D, Kaloumenou I, Theodoridis C. Evolution of glucose intolerance and diabetes in transfused patients with thalassemia. Pediatr Endocrinol Rev 2004, 2(Suppl 2): 267–71.

    PubMed  Google Scholar 

  86. Suvarna J, Ingle H, Deshmukh CT. Insulin resistance and beta cell function in chronically transfused patients of thalassemia major. Indian Pediatr 2006, 43: 393–400.

    PubMed  Google Scholar 

  87. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev 2007, 5: 642–8.

    PubMed  Google Scholar 

  88. Livadas DP, Economou E, Sofroniadou K, et al. A study of betacell function afterglucagon stimulation in thalassaemia major treated by high transfusion programme. Clin Endocrinol (Oxf) 1987, 27: 485–90.

    CAS  Google Scholar 

  89. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988, 63: 58–62.

    PubMed Central  PubMed  Google Scholar 

  90. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331: 567–73.

    CAS  PubMed  Google Scholar 

  91. Chern JP, Lin KH, Lu MY, et al. Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients. Diabetes Care 2001, 24: 850–4.

    CAS  PubMed  Google Scholar 

  92. Cario H, Holl RW, Debatin KM, Kohne E. Disproportionately elevated fasting proinsulin levels in normoglycemic patients with thalassemia major are correlated to the degree of iron overload. Horm Res 2003, 59: 73–8.

    CAS  PubMed  Google Scholar 

  93. Zuppinger K, Molinari B, Hirt A, et al. Increased risk of diabetes mellitus in beta-thalassemia major due to iron overload. Helv Paediatr Acta 1979, 34: 197–207.

    CAS  PubMed  Google Scholar 

  94. Sougleri M, Labropoulou-Karatza C, Paraskevopoulou P, Fragopanagou H, Alexandrides T. Chronic hepatitis C virus infection without cirrhosis induces insulin resistance in patients with alpha-thalassaemia major. Eur J Gastroenterol Hepatol 2001, 13: 1195–9.

    CAS  PubMed  Google Scholar 

  95. Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM. Abnormal glucose tolerance in Egyptian beta-thalassemic patients: possible association with genotyping. Pediatr Diabetes 2004, 5: 126–32.

    CAS  PubMed  Google Scholar 

  96. Mowla A, Karimi M, Afrasiabi A, De Sanctis V. Prevalence of diabetes mellitus and impaired glucose tolerance in beta-thalassemia patients with and without hepatitis C virus infection. Pediatr Endocrinol Rev 2004, 2(Suppl 2): 282–4.

    PubMed  Google Scholar 

  97. Saudek CD, Hemm RM, Peterson CM. Abnormal glucose tolerance in beta-thalassemia major. Metabolism 1977, 26: 43–52.

    CAS  PubMed  Google Scholar 

  98. el-Hazmi MA, al-Swailem A, al-Fawaz I, Warsey AS, al-Swailem A. Diabetes mellitus in children suffering from beta-thalassaemia. J Trop Pediatr 1994, 40: 261–6.

    CAS  PubMed  Google Scholar 

  99. Cavallo L, Trentadue RF, Liuzzi S, et al. A transverse and longitudinal study of pancreatic function and glucose tolerance in thalassemic patients. In: Endocrine disorders in thalassemia. Andò S, Brancati C eds. Berlin: Springer Verlag. 1995, 153–5.

    Google Scholar 

  100. Flynn DM, Fairney A, Jackson D, Clayton BE. Hormonal changes in thalassaemia major. Arch Dis Child 1976, 51: 828–36.

    CAS  PubMed Central  PubMed  Google Scholar 

  101. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988, 318: 809–14.

    CAS  PubMed  Google Scholar 

  102. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993, 77: 478–83.

    CAS  PubMed  Google Scholar 

  103. Cavallo-Perin P, Pacini G, Cerutti F, et al. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 1995, 44: 281–6.

    CAS  PubMed  Google Scholar 

  104. Pappas S, Donohue SM, Denver AE, Mohamed-Ali V, Goubet S, Yudkin JS. Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. Metabolism 1996, 45: 652–7.

    CAS  PubMed  Google Scholar 

  105. Cario H, Holl RW, Debatin KM, Kohne E. Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr 2003, 162: 139–46.

    CAS  PubMed  Google Scholar 

  106. Angelopoulos NG, Zervas A, Livadas S, et al. Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major. Diabet Med 2006, 23: 1327–31.

    CAS  PubMed  Google Scholar 

  107. Rodacki M, Pereira JR, Nabuco de Oliveira AM, et al. Ethnicity and young age influence the frequency of diabetic ketoacidosis at the onset of type 1 diabetes. Diabetes Res Clin Pract 2007, 78: 259–62.

    CAS  PubMed  Google Scholar 

  108. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006, 134: 438–44.

    CAS  PubMed  Google Scholar 

  109. Christoforidis A, Perifanis V, Tsatra I, Vlachaki E, Athanassiou-Metaxa M. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy. Diabetes Res Clin Pract 2007, 76: 6–11.

    CAS  PubMed  Google Scholar 

  110. Jones TW, Boulware SD, Caprio S, et al. Correction of hyperinsulinemia by glyburide treatment in nondiabetic patients with thalassemia major. Pediatr Res 1993, 33: 497–500.

    CAS  PubMed  Google Scholar 

  111. Ladis V, Theodorides C, Palamidou F, Frissiras S, Berdousi H, Kattamis C. Glucose disturbances and regulation with glibenclamide in thalassemia. J Pediatr Endocrinol Metab 1998, 11(Suppl 3): 871–8.

    PubMed  Google Scholar 

  112. Ladis V, Theodorides C, Palamidou F, Frissiras S, Berdousi H, Kattamis C. Regulation of glucose disturbances with glibenclamide in patients with thalassemia. Ann N Y Acad Sci 1998, 850: 471–4.

    CAS  PubMed  Google Scholar 

  113. Mangiagli A, Campisi S, De Sanctis V, et al; Study Group of the Italian Pediatrie and Diabetes Soceity (SIEDP) on Endocrine Complications in Non-Endocrine Disease. Effects of acarbose in beta-thalassaemia major patients with normal glucose tolerance and hyperinsulinism. Pediatr Endocrinol Rev 2004, 2(Suppl 2): 272–5.

    PubMed  Google Scholar 

  114. Cavallo L, Licci D, Acquafredda A, et al. Endocrine involvement in children with beta-thalassaemia major. Transverse and longitudinal studies. I. Pituitary-thyroidal axis function and its correlation with serum ferritin levels. Acta Endocrinol (Copenh) 1984, 107: 49–53.

    CAS  Google Scholar 

  115. Jain M, Sinha RS, Chellani H, Anand NK. Assessment of thyroid functions and its role in body growth in thalassemia major. Indian Pediatr 1995, 32: 213–9.

    CAS  PubMed  Google Scholar 

  116. Zervas A, Katopodi A, Protonotariou A, et al. Assessment of thyroid function in two hundred patients with beta-thalassemia major. Thyroid 2002, 12: 151–4.

    PubMed  Google Scholar 

  117. Cavallo L, Mautone A, Altomare M, Licciulli M, Pascazio A, Schettini F. Pituitary-thyroid function in children with beta-thalassaemia major. Acta Endocrinol (Copenh) 1981, 96: 59–64.

    CAS  Google Scholar 

  118. Phenekos C, Karamerou A, Pipis P, et al. Thyroid function in patients with homozygous beta-thalassaemia. Clin Endocrinol (Oxf) 1984, 20: 445–50.

    CAS  Google Scholar 

  119. Magro S, Puzzonia P, Consarino C, et al. Hypothyroidism in patients with thalassemia syndromes. Acta Haematol 1990, 84: 72–6.

    CAS  PubMed  Google Scholar 

  120. Agarwal MB, Shah S, Vishwanathan C, et al. Thyroid dysfunction in multi-transfused iron loaded thalassemia patients. Indian Pediatr 1992, 29: 997–1002.

    CAS  PubMed  Google Scholar 

  121. Landau H, Matoth I, Landau-Cordova Z, Goldfarb A, Rachmilewitz EA, Glaser B. Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clin Endocrinol (Oxf) 1993, 38: 55–61.

    CAS  Google Scholar 

  122. Filosa A, Di Maio S, Aloj G, Acampora C. Longitudinal study on thyroid function in patients with thalassemia major. J Pediatr Endocrinol Metab 2006, 19: 1397–404.

    CAS  PubMed  Google Scholar 

  123. Pitrolo L, Malizia G, Lo Pinto C, Malizia V, Capra M. Ultrasound thyroid evaluation in thalassemic patients: correlation between the aspects of thyroidal stroma and function. Pediatr Endocrinol Rev 2004, 2(Suppl 2): 313–5.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unità Operativa Complessa di Pediatria, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG)

    M. Delvecchio

  2. Dipartimento di Biomedicina dell’Età Evolutiva, Università di Bari, Piazza Giulio Cesare 11, 70124, Bari, Italy

    L. Cavallo MD

Authors
  1. M. Delvecchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Cavallo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Cavallo MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Delvecchio, M., Cavallo, L. Growth and endocrine function in thalassemia major in childhood and adolescence. J Endocrinol Invest 33, 61–68 (2010). https://doi.org/10.1007/BF03346551

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346551

Key-words

Search

Navigation